• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    OraSure Technologies Announces the Retirement of Jack E. Jerrett and Appointment of Agnieszka M. Gallagher as General Counsel, Chief Compliance Officer and Secretary

    11/9/21 7:05:00 AM ET
    $OSUR
    Medical/Dental Instruments
    Health Care
    Get the next $OSUR alert in real time by email

    BETHLEHEM, Pa., Nov. 09, 2021 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ:OSUR), a global leader in point-of-care and home diagnostic testing and sample collection technologies, announced today that after almost 21 years of service to the Company, Jack E. Jerrett is retiring as the Company's Senior Vice President, General Counsel, Chief Compliance Officer and Secretary, effective as of December 31, 2021. Agnieszka M. Gallagher, who most recently served as the Chief Ethics and Compliance Officer at Alnylam Pharmaceuticals has been hired by the Company to fill Jack's roles as the new General Counsel, Chief Compliance Officer and Secretary.

    "Jack has been a stalwart and extremely dedicated member of OraSure's executive leadership team for over two decades and his countless contributions to the Company's growth and development deserve our significant gratitude and appreciation," said Stephen S. Tang, Ph.D., President and Chief Executive Officer of OraSure Technologies. "While Jack's leadership, experience, and friendship will be sorely missed by the organization, we are fortunate to have an outstanding replacement with Aggie joining the Company and we are exceptionally pleased to add her to the executive leadership team."

    Ms. Gallagher, age 48, brings to OraSure a strong background with over two decades of legal and compliance executive leadership experience. Most recently, Ms. Gallagher served as the Chief Ethics and Compliance Officer for Alnylam Pharmaceuticals, a large cap biopharmaceutical company focused on RNAi therapeutics. Prior to joining Alnylam, Ms. Gallagher was the General Counsel, Secretary, and Chief Compliance Officer of ViiV Healthcare, overseeing a multi-billion dollar annual business. Before ViiV Healthcare, Ms. Gallagher served on GSK Vaccines executive team as Vice President, Ethics and Compliance Officer, and prior to that she led GSK Vaccines' legal and antitrust work following its $5 billion acquisition of Novartis Vaccines. Before joining GSK, Ms. Gallagher served in leadership roles in the legal and compliance functions at Sandoz (a Novartis Company), Medtronic Inc., and Pfizer Inc.  

    Mrs. Gallagher holds a Juris Doctorate from Rutgers Law School and a Bachelor of Arts Degree in Spanish from Rutgers College.

    About OraSure Technologies

    OraSure Technologies empowers the global community to improve health and wellness by providing access to accurate, essential information. OraSure, together with its wholly-owned subsidiaries, DNA Genotek, Diversigen, and Novosanis, provides its customers with end-to-end solutions that encompass tools, services and diagnostics. The OraSure family of companies is a leader in the development, manufacture, and distribution of rapid diagnostic tests, sample collection and stabilization devices, and molecular services solutions designed to discover and detect critical medical conditions. OraSure's portfolio of products is sold globally to clinical laboratories, hospitals, physician's offices, clinics, public health and community-based organizations, research institutions, government agencies, pharma, commercial entities and direct to consumers. For more information on OraSure Technologies, please visit www.orasure.com.

    Investor Contact:Media Contact:
    Scott GleasonAmy Koch
    Interim CFO & SVP Investor Relations & Corp. CommunicationsSr. Mgr. Corporate Communications
    484-425-0588484-523-1815
    [email protected][email protected]


    Primary Logo

    Get the next $OSUR alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $OSUR

    DatePrice TargetRatingAnalyst
    1/3/2023$5.00In-line
    Evercore ISI
    2/24/2022$15.00 → $12.00Buy
    Citigroup
    9/22/2021Outperform → Market Perform
    Raymond James
    8/4/2021$11.00 → $12.50Outperform
    Raymond James
    6/28/2021$12.00 → $11.00Outperform
    Raymond James
    More analyst ratings

    $OSUR
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    OraSure Announces Second Quarter 2025 Financial Results

    BETHLEHEM, Pa., Aug. 05, 2025 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ:OSUR), a leader in point-of-need and home diagnostic tests and sample management solutions, today announced its financial results for the three months ended June 30, 2025. "Our Q2 results were consistent with our expectations. We are making significant progress on our initiatives to expand our product portfolio, including launching our novel blood collection device for proteomic research in July. We are also staying closely aligned with our customers as they navigate an environment with improving, but still elevated, levels of uncertainty related to funding for public health programs and research," said C

    8/5/25 4:05:00 PM ET
    $OSUR
    Medical/Dental Instruments
    Health Care

    OraSure Appoints Anne Messing as Chief Commercial Officer

    BETHLEHEM, Pa., Aug. 04, 2025 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. ("OTI") (NASDAQ:OSUR), a leader in point-of-need and home diagnostic tests and sample management solutions, today announced that Anne Messing has joined OTI as Chief Commercial Officer. Ms. Messing brings more than 25 years of commercial leadership experience across the healthcare industry, including in life sciences, diagnostics, and clinical laboratory services, with a proven track record of driving growth, building high-performing sales teams, and transforming strategic vision into demonstrable results and sustainable success. In her role at OTI, she will be responsible for Sales, Marketing, Strategic Alliance

    8/4/25 7:05:00 AM ET
    $OSUR
    Medical/Dental Instruments
    Health Care

    OraSure to Announce Second Quarter 2025 Financial Results and Host Earnings Call on August 5th

    BETHLEHEM, Pa., July 21, 2025 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ:OSUR) has scheduled its regular earnings conference call covering second quarter 2025 financial results and certain business developments for 5 p.m. ET on August 5, 2025. A webcast of the conference call will be available on the investor relations page of OraSure's website at https://orasure.gcs-web.com/events-and-presentations. Please click on the webcast link and follow the prompts for registration and access at least 10 minutes prior to the call. The webcast will be archived on OraSure's website shortly after the call has ended and will be available for approximately one year. For participants int

    7/21/25 4:05:00 PM ET
    $OSUR
    Medical/Dental Instruments
    Health Care

    $OSUR
    SEC Filings

    View All

    Amendment: SEC Form SCHEDULE 13G/A filed by OraSure Technologies Inc.

    SCHEDULE 13G/A - ORASURE TECHNOLOGIES INC (0001116463) (Subject)

    9/3/25 4:31:20 PM ET
    $OSUR
    Medical/Dental Instruments
    Health Care

    SEC Form 10-Q filed by OraSure Technologies Inc.

    10-Q - ORASURE TECHNOLOGIES INC (0001116463) (Filer)

    8/6/25 4:37:31 PM ET
    $OSUR
    Medical/Dental Instruments
    Health Care

    OraSure Technologies Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - ORASURE TECHNOLOGIES INC (0001116463) (Filer)

    8/5/25 4:07:23 PM ET
    $OSUR
    Medical/Dental Instruments
    Health Care

    $OSUR
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Kenny John P. was granted 6,118 shares, increasing direct ownership by 4% to 153,322 units (SEC Form 4)

    4 - ORASURE TECHNOLOGIES INC (0001116463) (Issuer)

    9/26/25 4:26:58 PM ET
    $OSUR
    Medical/Dental Instruments
    Health Care

    Chief Financial Officer Mcgrath Kenneth J covered exercise/tax liability with 12,524 shares, decreasing direct ownership by 3% to 448,463 units (SEC Form 4)

    4 - ORASURE TECHNOLOGIES INC (0001116463) (Issuer)

    8/11/25 4:24:33 PM ET
    $OSUR
    Medical/Dental Instruments
    Health Care

    Director Mcmahon Robert W. covered exercise/tax liability with 7,317 shares, decreasing direct ownership by 7% to 99,919 units (SEC Form 4)

    4 - ORASURE TECHNOLOGIES INC (0001116463) (Issuer)

    8/4/25 4:58:03 PM ET
    $OSUR
    Medical/Dental Instruments
    Health Care

    $OSUR
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Evercore ISI resumed coverage on OraSure with a new price target

    Evercore ISI resumed coverage of OraSure with a rating of In-line and set a new price target of $5.00

    1/3/23 8:07:55 AM ET
    $OSUR
    Medical/Dental Instruments
    Health Care

    Citigroup reiterated coverage on OraSure Technologies with a new price target

    Citigroup reiterated coverage of OraSure Technologies with a rating of Buy and set a new price target of $12.00 from $15.00 previously

    2/24/22 8:34:18 AM ET
    $OSUR
    Medical/Dental Instruments
    Health Care

    OraSure Technologies downgraded by Raymond James

    Raymond James downgraded OraSure Technologies from Outperform to Market Perform

    9/22/21 5:02:16 AM ET
    $OSUR
    Medical/Dental Instruments
    Health Care

    $OSUR
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Gagliano Nancy J bought $39,270 worth of shares (12,750 units at $3.08), increasing direct ownership by 16% to 91,524 units (SEC Form 4)

    4 - ORASURE TECHNOLOGIES INC (0001116463) (Issuer)

    3/3/25 9:08:13 AM ET
    $OSUR
    Medical/Dental Instruments
    Health Care

    President & CEO Eglinton Manner Carrie bought $100,027 worth of shares (28,670 units at $3.49), increasing direct ownership by 2% to 1,288,334 units (SEC Form 4)

    4 - ORASURE TECHNOLOGIES INC (0001116463) (Issuer)

    3/3/25 9:07:25 AM ET
    $OSUR
    Medical/Dental Instruments
    Health Care

    President & CEO Eglinton Manner Carrie bought $247,378 worth of shares (78,625 units at $3.15), increasing direct ownership by 7% to 1,259,664 units (SEC Form 4)

    4 - ORASURE TECHNOLOGIES INC (0001116463) (Issuer)

    2/27/25 9:14:53 PM ET
    $OSUR
    Medical/Dental Instruments
    Health Care

    $OSUR
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by OraSure Technologies Inc.

    SC 13G/A - ORASURE TECHNOLOGIES INC (0001116463) (Subject)

    11/12/24 4:46:06 PM ET
    $OSUR
    Medical/Dental Instruments
    Health Care

    Amendment: SEC Form SC 13G/A filed by OraSure Technologies Inc.

    SC 13G/A - ORASURE TECHNOLOGIES INC (0001116463) (Subject)

    11/4/24 1:18:55 PM ET
    $OSUR
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G filed by OraSure Technologies Inc.

    SC 13G - ORASURE TECHNOLOGIES INC (0001116463) (Subject)

    10/4/24 1:30:36 PM ET
    $OSUR
    Medical/Dental Instruments
    Health Care

    $OSUR
    Leadership Updates

    Live Leadership Updates

    View All

    OraSure Appoints Anne Messing as Chief Commercial Officer

    BETHLEHEM, Pa., Aug. 04, 2025 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. ("OTI") (NASDAQ:OSUR), a leader in point-of-need and home diagnostic tests and sample management solutions, today announced that Anne Messing has joined OTI as Chief Commercial Officer. Ms. Messing brings more than 25 years of commercial leadership experience across the healthcare industry, including in life sciences, diagnostics, and clinical laboratory services, with a proven track record of driving growth, building high-performing sales teams, and transforming strategic vision into demonstrable results and sustainable success. In her role at OTI, she will be responsible for Sales, Marketing, Strategic Alliance

    8/4/25 7:05:00 AM ET
    $OSUR
    Medical/Dental Instruments
    Health Care

    KKR, CrowdStrike Holdings and GoDaddy Set to Join S&P 500; Others to Join S&P MidCap 400 and S&P SmallCap 600

    NEW YORK, June 7, 2024 /PRNewswire/ -- S&P Dow Jones Indices ("S&P DJI") will make the following changes to the S&P 500, S&P MidCap 400, and S&P SmallCap 600 indices effective prior to the open of trading on Monday, June 24, to coincide with the quarterly rebalance. The changes ensure each index is more representative of its market capitalization range. All companies being added to the S&P 500 are more representative of the large-cap market space, all companies being added to the S&P MidCap 400 are more representative of the mid-cap market space, and all companies being added to the S&P SmallCap 600 are more representative of the small-cap market space. The companies being removed from the S

    6/7/24 6:09:00 PM ET
    $ADTN
    $ALTR
    $ATNI
    Telecommunications Equipment
    Utilities
    Computer Software: Prepackaged Software
    Technology

    NOWDiagnostics Welcomes Dr. Stephen S. Tang as Chairman of the Board

    Former Head of OraSure Technologies Joins at Key Stage Leading up to Company's Product Launch NOWDiagnostics (NOWDx), a developer of over-the-counter (OTC) and point-of-care (POC) diagnostics tests and first-in-class technology and platforms, today announced the appointment of Dr. Stephen S. Tang, Ph.D., MBA, as the chairman of the company's board of directors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240321747977/en/NOWDiagnostics (NOWDx) Welcomes Dr. Stephen S. Tang as Chairman of the Board (Photo: Business Wire) Dr. Tang is a longtime veteran of the medical diagnostic industry. He led OraSure Technologies, Inc. (NASDA

    3/21/24 8:31:00 AM ET
    $OSUR
    Medical/Dental Instruments
    Health Care

    $OSUR
    Financials

    Live finance-specific insights

    View All

    OraSure Announces Second Quarter 2025 Financial Results

    BETHLEHEM, Pa., Aug. 05, 2025 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ:OSUR), a leader in point-of-need and home diagnostic tests and sample management solutions, today announced its financial results for the three months ended June 30, 2025. "Our Q2 results were consistent with our expectations. We are making significant progress on our initiatives to expand our product portfolio, including launching our novel blood collection device for proteomic research in July. We are also staying closely aligned with our customers as they navigate an environment with improving, but still elevated, levels of uncertainty related to funding for public health programs and research," said C

    8/5/25 4:05:00 PM ET
    $OSUR
    Medical/Dental Instruments
    Health Care

    OraSure to Announce Second Quarter 2025 Financial Results and Host Earnings Call on August 5th

    BETHLEHEM, Pa., July 21, 2025 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ:OSUR) has scheduled its regular earnings conference call covering second quarter 2025 financial results and certain business developments for 5 p.m. ET on August 5, 2025. A webcast of the conference call will be available on the investor relations page of OraSure's website at https://orasure.gcs-web.com/events-and-presentations. Please click on the webcast link and follow the prompts for registration and access at least 10 minutes prior to the call. The webcast will be archived on OraSure's website shortly after the call has ended and will be available for approximately one year. For participants int

    7/21/25 4:05:00 PM ET
    $OSUR
    Medical/Dental Instruments
    Health Care

    OraSure Announces First Quarter 2025 Financial Results

    BETHLEHEM, Pa., May 07, 2025 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ:OSUR), a leader in point-of-need and home diagnostic tests and sample management solutions, today announced its financial results for the three months ended March 31, 2025. "Our Q1 results were consistent with our expectations. Our customers continue to demonstrate their preference for our differentiated products in delivering on their important health objectives, even while uncertainty remains elevated related to government funding sources for some segments," said OraSure President and CEO Carrie Eglinton Manner. "We are making good progress in advancing our innovation roadmap, including multiple new prod

    5/7/25 4:05:00 PM ET
    $OSUR
    Medical/Dental Instruments
    Health Care